Skip to main content

Advertisement

Table 2 Overall survival and clinicopathological variables in 85 patients with PDAC

From: Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma

Variables Hazard ratio (95% CI) p-value
Univariate analysis
 Age (< 65 vs ≥65) 0.98 (0.59–1.62) .94
 Gender (male vs. female) 1.13 (0.68–1.88) .65
 Tumor size (<  2 cm vs. ≥ 2 cm) 2.11 (1.07–4.16) .03
 Stage (I/II vs. III/IV) 0.74 (0.44–1.26) .28
 Grade (low vs. high) 1.84 (1.11–3.05) .02
 PNI 1.18 (0.70–2.01) .54
 LVI 1.46 (0.90–2.40) .13
 LN metastasis 1.31 (0.77–2.21) .32
 HNF-1B (negative vs. positive) 1.34 (0.70–2.57) .38
 No neoadjuvant 1.14 (0.41–1.14) .80
Multivariate analysis
 Tumor size (<  2 cm vs. ≥ 2 cm) 2.10 (1.06–4.16) .03
 Grade (low vs. high) 1.83 (1.10–3.06) .02
  1. Abbreviations: PDAC, pancreatic ductal adenocarcinoma; VS, versus;
  2. SD standard deviation, LVI lymphovascular invasion;
  3. LN lymph node, PNI perineural invasion
  4. Bold: Statistically significant